Houdini Bio secures £1.5m to improve gene and cell therapies

Houdini Bio, a University of Cambridge spinout, raised nearly £1.5m to improve gene and cell therapies. The startup's technology redesigns therapeutic DNA to bypass the body's defense mechanisms, enabling longer activity and lower doses. Preclinical data shows over tenfold increase in gene expression versus competitors.